During pregnancy, elevated levels of type I interferon are associated with complications such as intrauterine growth restriction, preterm birth, and fetal death, yet the underlying mechanisms have remained poorly understood. This work focuses on a key step in placental development: the fusion of trophoblast cells into a multinucleated layer called the syncytiotrophoblast. This fusion relies on syncytins, proteins derived from the envelopes of ancestral endogenous retroviruses captured by mammals during evolution; inactivation of syncytin genes in mice leads to growth restriction and mid-gestation lethality. An abnormal syncytiotrophoblast is also observed in several human pregnancy disorders.
The authors examined the role of interferon-induced transmembrane proteins (IFITM1, IFITM2, and IFITM3), a family of restriction factors known to block the entry of numerous enveloped viruses by inhibiting virus–cell fusion at the hemifusion stage, through alteration of the biophysical properties and cholesterol content of membranes. By combining human trophoblast cultures and murine cells, the team establishes that IFITMs impede syncytiotrophoblast formation and inhibit syncytin-mediated fusion. In primary villous cytotrophoblasts isolated from term human placentas, interferon-beta strongly induces IFITMs and reduces fusion as well as the secretion of human chorionic gonadotropin, without any increase in an apoptosis marker, ruling out a mere cytotoxic effect. At the single-cell level, cells expressing IFITM3 remained mononucleated even in the vicinity of large syncytia.
In pregnant mice, administration of the interferon inducer polyinosinic–polycytidylic acid (Poly-IC) at embryonic day 7.5, shortly before syncytiotrophoblast formation, caused resorption of nearly all wild-type fetuses. In contrast, fetuses lacking the interferon receptor (Ifnar) or all Ifitm genes were protected. Ifitm-deleted mice nonetheless responded normally to Poly-IC, as evidenced by the systemic induction of various interferon-stimulated genes, placing the protective effect at the level of the IFITMs themselves. Histological analysis confirmed a reduction of the syncytiotrophoblast in treated wild-type placentas, whereas it remained present in deleted animals; IFITM3 was induced in trophoblasts in response to treatment.
This work thus reveals a previously unknown function of this family of antiviral restriction factors and offers a molecular explanation for the placental dysfunctions associated with interferon-related disorders, whether congenital infections or genetic and autoimmune interferonopathies. The authors suggest that blocking IFITMs could represent a conceivable intervention strategy against pregnancy complications linked to interferonopathies.